

FILE 'HOME' ENTERED AT 13:39:55 ON 05 MAR 2003

L1 QUE VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHYLAMINOETHANE) (S) CARBAMOYL))

L2 QUE L1 OR VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHYLAMINOETHANE) (S) CHOLESTEROL))

d rank

F1	131	USPATFULL
F2	21	CAPLUS
F3	9	IFIPAT
F4	9	TOXCENTER
F5	8	WPIDS
F6	8	WPINDEX
F7	5	BIOTECHNO
F8	5	DRUGU
F9	5	EMBASE
F10	4	BIOSIS
F11	4	DDFU
F12	4	LIFESCI
F13	4	PASCAL
F14	3	ESBIOBASE
F15	3	MEDLINE
F16	3	SCISEARCH
F17	2	BIOTECHABS
F18	2	BIOTECHDS
F19	2	CANCERLIT
F20	2	PROMT
F21	2	USPAT2
F22	1	DRUGUPDATES
F23	1	PHIN
L3	47	L1 OR VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHYLAMINOETHANE) (S) CHOLESTEROL))
L4	23	DUP REM L3 (24 DUPLICATES REMOVED)
L5	32	ADJUVANT (S) (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHYLAMINOETHANE) (S) (CARBAMOYL OR CHOLESTEROL)))
L6	11	DUP REM L5 (21 DUPLICATES REMOVED)
L7	25	L6 OR L4
L8	24	DUP REM L7 (1 DUPLICATE REMOVED)

d his

(FILE 'HOME' ENTERED AT 13:39:55 ON 05 MAR 2003)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 13:40:54 ON 05 MAR 2003

SEA VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHYLAMINO

4	FILE BIOSIS
2	FILE BIOTECHABS
2	FILE BIOTECHDS
5	FILE BIOTECHNO
2	FILE CANCERLIT
20	FILE CAPLUS
4	FILE DDFU
5	FILE DRUGU
1	FILE DRUGUPDATES
5	FILE EMBASE
3	FILE ESBIOBASE
0*	FILE FEDRIP
9	FILE IFIPAT

4 FILE LIFESCI
 3 FILE MEDLINE
 4 FILE PASCAL
 1 FILE PHIN
 2 FILE PROMT
 3 FILE SCISEARCH
 9 FILE TOXCENTER
 129 FILE USPATFULL
 2 FILE USPAT2
 8 FILE WPIDS
 8 FILE WPINDEX

L1 QUE VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHYLAMINO

 SEA L1 OR VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHY

 4 FILE BIOSIS
 2 FILE BIOTECHABS
 2 FILE BIOTECHDS
 5 FILE BIOTECHNO
 2 FILE CANCERLIT
 21 FILE CAPLUS
 4 FILE DDFU
 5 FILE DRUGU
 1 FILE DRUGUPDATES
 5 FILE EMBASE
 3 FILE ESBIODBASE
 0* FILE FEDRIP
 9 FILE IFIPAT
 4 FILE LIFESCI
 3 FILE MEDLINE
 4 FILE PASCAL
 1 FILE PHIN
 2 FILE PROMT
 3 FILE SCISEARCH
 9 FILE TOXCENTER
 131 FILE USPATFULL
 2 FILE USPAT2
 8 FILE WPIDS
 8 FILE WPINDEX

L2 QUE L1 OR VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHY

 FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHNO, EMBASE, TOXCENTER' ENTERED AT
 13:47:09 ON 05 MAR 2003

L3 47 S L1 OR VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHYLA
 L4 23 DUP REM L3 (24 DUPLICATES REMOVED)
 L5 32 S ADJUVANT (S) (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHYLAMINOE
 L6 11 DUP REM L5 (21 DUPLICATES REMOVED)
 L7 25 S L6 OR L4
 L8 24 DUP REM L7 (1 DUPLICATE REMOVED)

d his

(FILE 'HOME' ENTERED AT 13:39:55 ON 05 MAR 2003)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI,
BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,
CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,
DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 13:40:54 ON
05 MAR 2003

SEA VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHYLAMINO

4 FILE BIOSIS
2 FILE BIOTECHABS
2 FILE BIOTECHDS
5 FILE BIOTECHNO
2 FILE CANCERLIT
20 FILE CAPLUS
4 FILE DDFU
5 FILE DRUGU
1 FILE DRUGUPDATES
5 FILE EMBASE
3 FILE ESBIODBASE
0* FILE FEDRIP
9 FILE IFIPAT
4 FILE LIFESCI
3 FILE MEDLINE
4 FILE PASCAL
1 FILE PHIN
2 FILE PROMT
3 FILE SCISEARCH
9 FILE TOXCENTER
129 FILE USPATFULL
2 FILE USPAT2
8 FILE WPIDS
8 FILE WPINDEX

L1

QUE VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHYLAMINO

SEA L1 OR VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHY

4 FILE BIOSIS
2 FILE BIOTECHABS
2 FILE BIOTECHDS
5 FILE BIOTECHNO
2 FILE CANCERLIT
21 FILE CAPLUS
4 FILE DDFU
5 FILE DRUGU
1 FILE DRUGUPDATES
5 FILE EMBASE
3 FILE ESBIODBASE
0* FILE FEDRIP
9 FILE IFIPAT
4 FILE LIFESCI
3 FILE MEDLINE
4 FILE PASCAL
1 FILE PHIN
2 FILE PROMT
3 FILE SCISEARCH
9 FILE TOXCENTER
131 FILE USPATFULL
2 FILE USPAT2

8 FILE WPIDS
8 FILE WPINDEX

L2 QUE L1 OR VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHY

FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHNO, EMBASE, TOXCENTER' ENTERED AT
13:47:09 ON 05 MAR 2003

L3 47 S L1 OR VACCINE AND (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHYLA
L4 23 DUP REM L3 (24 DUPLICATES REMOVED)
L5 32 S ADJUVANT (S) (DC-CHOL OR ((POLYETHYLENAMINE OR DIMETHYLAMINOE
L6 11 DUP REM L5 (21 DUPLICATES REMOVED)
L7 25 S L6 OR L4
L8 24 DUP REM L7 (1 DUPLICATE REMOVED)
L9 4 S AMPHIPATHIC (S) ADJUVANT AND (CARBAMOYL OR CHOLESTEROL)

L8 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:594655 CAPLUS
 DN 137:159311
 TI Polymer combinations that result in stabilized aerosols for gene delivery to the lungs
 IN Zou, Yiyu; Perez-Soler, Roman
 PA Board of Regents, The University of Texas System, USA
 SO PCT Int. Appl., 136 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060412	A2	20020808	WO 2002-US2909	20020201
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002187105	A1	20021212	US 2002-61444	20020201
PRAI	US 2001-266174P	P	20010201		

L8 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:275825 CAPLUS
 DN 136:299680
 TI **Vaccine** composition comprising an antigen, a cationic lipid and an immunostimulatory oligonucleotide
 IN Haensler, Jean; Hurpin, Christian Marcel
 PA Aventis Pasteur, Fr.
 SO PCT Int. Appl., 17 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002028428	A2	20020411	WO 2001-FR3098	20011008
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR 2814958	A1	20020412	FR 2000-12808	20001006
	AU 2001095673	A5	20020415	AU 2001-95673	20011008
PRAI	FR 2000-12808	A	20001006		
	WO 2001-FR3098	W	20011008		

L8 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:71901 CAPLUS
 DN 136:133603
 TI Immunological combinations for prophylaxis and therapy of Helicobacter

pylori infection
 IN Guy, Bruno; Haensler, Jean
 PA Merieux Oravax, Fr.
 SO PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002005845	A1	20020124	WO 2001-EP9031	20010704
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,				
	HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,				
	RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,				
	VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	EP 2000-420148	A	20000705		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:736708 CAPLUS
 DN 137:246541
 TI Subunit respiratory syncytial virus preparation
 IN Cates, George A.; Sanhueza, Sonia E.; Oomen, Raymond P.; Klein, Michel H.
 PA Can.
 SO U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. 6,309,649.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002136739	A1	20020926	US 2001-950655	20010913
	US 6020182	A	20000201	US 1996-679060	19960712
	WO 9802457	A1	19980122	WO 1997-CA497	19970711
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,				
	LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,				
	VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				
	GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,				
	GN, ML, MR, NE, SN, TD, TG				
PRAI	US 6309649	B1	20011030	US 1999-214605	19990503
	US 1996-679060	A2	19960712		
	WO 1997-CA497	A2	19970711		
	US 1999-214605	A2	19990503		

L8 ANSWER 5 OF 24 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
 AN 2003:14677 BIOSIS
 DN PREV200300014677
 TI Use of an amphipathic compound for providing an adjuvant to a subunit
vaccine.
 AU Darbouret, Anne (1); Brunel, Florence; Ronco, Jorge
 CS (1) Saint Maurice sur Dargoire, France France
 ASSIGNEE: Aventis Pasteur S.A., France

PI US 6472159 October 29, 2002
SO Official Gazette of the United States Patent and Trademark Office Patents,
(Oct. 29 2002) Vol. 1263, No. 5, pp. No Pagination.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
ISSN: 0098-1133.

DT Patent
LA English

L8 ANSWER 6 OF 24 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V.
AN 2002:35247524 BIOTECHNO
TI Prospects for cationic polymers in gene and oligonucleotide therapy
against cancer
AU Merdan T.; Kopecek J.; Kissel T.
CS T. Kissel, Department of Pharmaceutics, Philipps University, Ketzertbach
63, 35032 Marburg, Germany.
E-mail: kissel@mail.uni-marburg.de

SO Advanced Drug Delivery Reviews, (13 SEP 2002), 54/5 (715-758), 292
reference(s)
CODEN: ADDREP ISSN: 0169-409X

PUI S0169409X02000467
DT Journal; General Review
CY Netherlands
LA English
SL English

L8 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2001:816486 CAPLUS
DN 135:356751
TI Immunizing against HIV infection
IN Rovinski, Benjamin; Tartaglia, James; Cao, Shi-Xian; Persson, Roy; Klein,
Michel H.
PA Aventis Pasteur Limited, Can.
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001082962	A2	20011108	WO 2001-CA577	20010425
	WO 2001082962	A3	20020321		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1280551	A2	20030205	EP 2001-927532	20010425
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2002051770	A1	20020502	US 2001-842883	20010427
PRAI	US 2000-200011P	P	20000427		
	WO 2001-CA577	W	20010425		

L8 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2001:167832 CAPLUS
DN 134:212748
TI Lipid-nucleic acid compositions for stimulating cytokine secretion and

inducing an immune response
 IN Semple, Sean C.; Harasym, Troy O.; Klimuk, Sandra K.; Kojic, Ljiljana D.;
 Bramson, Jonathan L.; Mui, Barbara; Hope, Michael J.
 PA Inex Pharmaceuticals Corp., Can.
 SO PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN. CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001015726	A2	20010308	WO 2000-CA1013	20000828
	WO 2001015726	A3	20010726		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2000068139	A5	20010326	AU 2000-68139	20000828
	BR 2000013834	A	20020423	BR 2000-13834	20000828
	EP 1212085	A2	20020612	EP 2000-956004	20000828
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
PRAI	US 2000-176406P	P	20000113		
	US 1999-151211P	P	19990826		
	WO 2000-CA1013	W	20000828		

L8 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:792220 CAPLUS
 DN 135:330483
 TI Subunit respiratory syncytial virus **vaccine** preparation
 IN Cates, George A.; Sanhueza, Sonia E.; Oomen, Raymond P.; Klein, Michel H.
 PA Aventis Pasteur Ltd., Can.
 SO U.S., 16 pp., Cont.-in-part of U.S. 6,020,182.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN. CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6309649	B1	20011030	US 1999-214605	19990503
	US 6020182	A	20000201	US 1996-679060	19960712
	WO 9802457	A1	19980122	WO 1997-CA497	19970711
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 2002136739	A1	20020926	US 2001-950655	20010913
PRAI	US 1996-679060	A2	19960712		
	WO 1997-CA497	W	19970711		
	US 1999-214605	A2	19990503		

RE. CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2003 ACS

AN 2001:791879 CAPLUS

DN 135:335117

TI Immunological adjuvants containing Hemagglutinating virus-containing charged liposomes, and manufacture thereof

IN Honda, Kazuo; Kaneda, Yasushi; Shiozaki, Koichi

PA Chemo-Sero-Therapeutic Research Institute, Japan

SO Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001302541	A2	20011031	JP 2000-128670	20000428
PRAI	JP 2000-128670		20000428		

L8 ANSWER 11 OF 24 MEDLINE

AN 2001214729 MEDLINE

DN 21108976 PubMed ID: 11166905

TI Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split **vaccine**.

AU Guy B; Pascal N; Francon A; Bonnin A; Gimenez S; Lafay-Vialon E; Tranoy E; Haensler J

CS Aventis Pasteur, Campus Merieux, 1541 Avenue Marcel Merieux 69280, Marcy l'Etoile, France.

SO VACCINE, (2001 Feb 8) 19 (13-14) 1794-805.

Journal code: 8406899. ISSN: 0264-410X.

CY England: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200104

ED Entered STN: 20010425

Last Updated on STN: 20010425

Entered Medline: 20010419

L8 ANSWER 12 OF 24 MEDLINE

AN 2001433489 MEDLINE

DN 21373978 PubMed ID: 11481628

TI Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice.

AU Lechmann M; Murata K; Satoi J; Vergalla J; Baumert T F; Liang T J

CS Liver Diseases Section, NIDDK, National Institutes of Health, Bethesda, MD 20892, USA.

SO HEPATOLOGY, (2001 Aug) 34 (2) 417-23.

Journal code: 8302946. ISSN: 0270-9139.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200108

ED Entered STN: 20010827

Last Updated on STN: 20010827

Entered Medline: 20010823

L8 ANSWER 13 OF 24 MEDLINE

DUPLICATE 1

AN 2001169738 MEDLINE

DN 21167510 PubMed ID: 11267850

TI Formulations of single or multiple H. pylori antigens with **DC Chol adjuvant** induce protection by the systemic route in

mice. Optimal prophylactic combinations are different from therapeutic ones.

AU Sanchez V; Gimenez S; Haensler J; Geoffroy C; Rokbi B; Seguin D; Lissolo L; Harris B; Rizvi F; Kleanthous H; Monath T; Cadoz M; Guy B
CS Aventis Pasteur, Campus Merieux, Research Department, Marcy l'Etoile, France.
SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, (2001 Mar) 30 (2) 157-65.
Journal code: 9315554. ISSN: 0928-8244.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200105
ED Entered STN: 20010529
Last Updated on STN: 20010529
Entered Medline: 20010524

L8 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2000:420985 CAPLUS
DN 133:57573
TI Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
IN Cates, George A.; Sambhara, Suryaprakash; Burt, David; Klein, Michel H.
PA Connaught Laboratories Limited, Can.
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000035481	A2	20000622	WO 1999-CA1194	19991216
	WO 2000035481	A3	20001026		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1140164	A2	20011010	EP 1999-957825	19991216
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRAI	US 1998-213770	A	19981217		
	WO 1999-CA1194	W	19991216		

L8 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2003 ACS
AN 2000:420981 CAPLUS
DN 133:57570
TI Multi-component **vaccine** comprising at least two antigens from Haemophilus influenzae to protect against disease
IN Loosmore, Sheena M.; Yang, Yan-ping; Klein, Michel H.
PA Connaught Laboratories Ltd., Can.
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI WO 2000035477 A2 20000622 WO 1999-CA1189 19991215
 WO 2000035477 A3 20001026
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2355466 AA 20000622 CA 1999-2355466 19991215
 EP 1140158 A2 20011010 EP 1999-957822 19991215
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2002532433 T2 20021002 JP 2000-587796 19991215
 PRAI US 1998-210995 A 19981215
 WO 1999-CA1189 W 19991215

L8 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2003 ACS

AN 2000:34710 CAPLUS

DN 132:83616

TI Use of an amphipathic compound for providing an adjuvant to a subunit
vaccine

IN Darbouret, Anne; Brunel, Florence; Ronco, Jorge

PA Pasteur Merieux Serums & Vaccins, Fr.

SO PCT Int. Appl., 11 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000001345	A2	20000113	WO 1999-FR1604	19990702
	W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	FR 2781160	A1	20000121	FR 1998-8700	19980703
	FR 2781160	B1	20000818		
	CA 2337048	AA	20000113	CA 1999-2337048	19990702
	AU 9946217	A1	20000124	AU 1999-46217	19990702
	EP 1093382	A2	20010425	EP 1999-929389	19990702
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		
	US 6472159	B1	20021029	US 2001-720863	20010416
PRAI	FR 1998-8700	A	19980703		
	WO 1999-FR1604	W	19990702		

L8 ANSWER 17 OF 24 MEDLINE

AN 1999294420 MEDLINE

DN 99294420 PubMed ID: 10367954

TI Cationic lipid **DC-Chol** induces an improved and
 balanced immunity able to overcome the unresponsiveness to the hepatitis B
vaccine.

AU Brunel F; Darbouret A; Ronco J
 CS Research Department, Pasteur Merieux Connaught, Marcy L'Etoile, France.
 SO VACCINE, (1999 Apr 23) 17 (17) 2192-203.
 Journal code: 8406899. ISSN: 0264-410X.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; AIDS
 EM 199907
 ED Entered STN: 19990806
 Last Updated on STN: 19990806
 Entered Medline: 19990727

L8 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:721602 CAPLUS
 DN 129:342686
 TI Anti-Helicobacter **vaccine** composition comprising a Th1 adjuvant
 IN Guy, Bruno; Haensler, Jean
 PA Merieux Oravax, Fr.
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9848836	A1	19981105	WO 1998-FR875	19980430
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,				
	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				
	CM, GA, GN, ML, MR, NE, SN, TD, TG				
	FR 2762787	A1	19981106	FR 1997-5608	19970430
	FR 2762787	B1	20001006		
	AU 9876584	A1	19981124	AU 1998-76584	19980430
	AU 750379	B2	20020718		
	EP 979100	A1	20000216	EP 1998-924360	19980430
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	BR 9809381	A	20000704	BR 1998-9381	19980430
	JP 2002505665	T2	20020219	JP 1998-546684	19980430
PRAI	FR 1997-5608	A	19970430		
	FR 1997-15732	A	19971208		
	WO 1998-FR875	W	19980430		

OS MARPAT 129:342686
 RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:354043 CAPLUS
 DN 126:329511
 TI Transferrin receptor protein of Moraxella
 IN Yang, Yan-Ping; Myers, Lisa E.; Harkness, Robin E.; Klein, Michel H.
 PA Connaught Laboratories Limited, Can.; Yang, Yan-Ping; Myers, Lisa E.;
 Harkness, Robin E.; Klein, Michel H.
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9713785	A1	19970417	WO 1996-CA684	19961011
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA			
	US 6290970	B1	20010918	US 1995-540753	19951011
	CA 2234409	AA	19970417	CA 1996-2234409	19961011
	AU 9672082	A1	19970430	AU 1996-72082	19961011
	AU 711791	B2	19991021		
	EP 866803	A1	19980930	EP 1996-933285	19961011
	EP 866803	B1	20021218		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	CN 1204344	A	19990106	CN 1996-198905	19961011
	JP 11500744	T2	19990119	JP 1996-514592	19961011
	AT 229979	E	20030115	AT 1996-933285	19961011
	US 6190668	B1	20010220	US 1998-51320	19980730
PRAI	US 1995-540753	A1	19951011		
	WO 1996-CA684	W	19961011		

L8 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2003 ACS

AN 1997:290545 CAPLUS

DN 126:263153

TI Parainfluenza virus glycoproteins and **vaccines**

IN Cates, George A.; Ewasyshyn, Mary E.; Fahim, Raafat E. F.; Jackson, Gail E. D.; Klein, Michel H.; Symington, Alison L.

PA Connaught Laboratories Limited, Can.; Cates, George A.; Ewasyshyn, Mary E.; Fahim, Raafat E. F.; Jackson, Gail E. D.; Klein, Michel H.; Symington, Alison L.

SO PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9711093	A2	19970327	WO 1996-CA639	19960923
	WO 9711093	A3	19970515		
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA			
	CA 2232515	AA	19970327	CA 1996-2232515	19960923
	AU 9669820	A1	19970409	AU 1996-69820	19960923
	AU 712213	B2	19991104		
	EP 851873	A2	19980708	EP 1996-930931	19960923
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	CN 1202905	A	19981223	CN 1996-198453	19960923
	JP 11513372	T2	19991116	JP 1996-512271	19960923
	BR 9610590	A	20001024	BR 1996-10590	19960923
	US 6165774	A	20001226	US 1998-43477	19980808

	AU 9932228	A1	19990805	AU 1999-32228	19990526
	AU 727996	B2	20010104		
	AU 9932229	A1	19990819	AU 1999-32229	19990526
	AU 732951	B2	20010503		
	AU 9932230	A1	19990819	AU 1999-32230	19990526
	AU 718025	B2	20000406		
PRAI	US 1995-532464	A	19950922		
	AU 1996-69820	A3	19960923		
	WO 1996-CA639	W	19960923		

L8 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:603190 CAPLUS
 DN 127:189653
 TI Lactoferrin receptor protein
 IN Schryvers, Anthony B.; Bonnah, Robert A.
 PA Connaught Laboratories Limited, Can.
 SO Can. Pat. Appl., 50 pp.
 CODEN: CPXXEB
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	CA 2162193	AA	19970503	CA 1995-2162193	19951106
	US 6048539	A	20000411	US 1995-552232	19951102
	US 6211343	B1	20010403	US 1999-370869	19990810
	US 6344200	B1	20020205	US 1999-371126	19990810
	US 6348198	B1	20020219	US 1999-371127	19990810
PRAI	US 1995-552232	A	19951102		

L8 ANSWER 22 OF 24 MEDLINE
 AN 1998010146 MEDLINE
 DN 98010146 PubMed ID: 9349433
 TI Protamine sulfate enhances lipid-mediated gene transfer.
 AU Sorgi F L; Bhattacharya S; Huang L
 CS Department of Pharmacology, University of Pittsburgh School of Medicine,
 PA 15261, USA.
 NC CA 59327 (NCI)
 CA 64654 (NCI)
 CA 71731 (NCI)
 +
 SO GENE THERAPY, (1997 Sep) 4 (9) 961-8.
 Journal code: 9421525. ISSN: 0969-7128.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199711
 ED Entered STN: 19971224
 Last Updated on STN: 19971224
 Entered Medline: 19971120

L8 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2003 ACS
 AN 1996:380149 CAPLUS
 DN 125:31928
 TI Major outer membrane protein CD of Moraxella
 IN Yang, Yan-Ping; Harkness, Robin E.; Myers, Lisa E.; McGuinness, Ursula;
 Klein, Michel H.
 PA Connaught Laboratories Limited, Can.
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9612733	A1	19960502	WO 1995-CA604	19951023
	W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6121427	A	20000919	US 1995-474394	19950607
	AU 9536953	A1	19960515	AU 1995-36953	19951023
	AU 706832	B2	19990624		
	EP 787144	A1	19970806	EP 1995-944810	19951023
	EP 787144	B1	20011212		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1174559	A	19980225	CN 1995-196963	19951023
	JP 10508303	T2	19980818	JP 1995-513562	19951023
	AT 210678	E	20011215	AT 1995-944810	19951023
	ES 2169166	T3	20020701	ES 1995-944810	19951023
	RU 2186582	C2	20020810	RU 1997-108362	19951023
PRAI	US 1994-328589	A	19941024		
	WO 1995-CA604	W	19951023		

L8 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2003 ACS

AN 1995:260263 CAPLUS

DN 122:29689

TI Induction of alloreactive cytotoxic T lymphocytes by intra-splenic immunization with allogeneic class I major histocompatibility complex DNA and **DC-cho1** cationic liposomes

AU Hui, Kam M.; Sabapathy, Tr. Kanaga; Oei, Audrey A.; Singhal, Arun; Huang, Leaf

CS Institute of Molecular and Cell Biology, National University of Singapore, Singapore, 0511, Singapore

SO Journal of Liposome Research (1994), 4(3), 1075-90

CODEN: JLREE7; ISSN: 0898-2104

DT Journal

LA English

immunization with allogeneic class I major histocompatibility complex DNA and **DC-cho1** cationic liposomes

AU Hui, Kam M.; Sabapathy, Tr. Kanaga; Oei, Audrey A.; Singhal, Arun; Huang, Leaf
CS Institute of Molecular and Cell Biology, National University of Singapore, Singapore, 0511, Singapore
SO Journal of Liposome Research (1994), 4(3), 1075-90
CODEN: JLREE7; ISSN: 0898-2104

DT Journal

LA English

AB A simple strategy for designing a cancer immunotherapeutic system involves modification of tumor cells from tumor-bearing animals in vivo in such a way that the host can evoke a specific immune response against them. We have expressed allogeneic class I major histocompatibility complex (MHC) mols. on tumor cells, through ex vivo DNA-mediated gene transfer. These mols. are potent immuno-modulators for the stimulation of strong immune reactions against certain malignancies. In order to achieve efficient gene delivery to tumor cells in vivo, we have compared the efficiencies of gene transfer into mammalian tumor cells by the biolistic particle delivery system and cationic liposomes. In this report, we have demonstrated that cationic liposomes prepd. by **DC-cho1** and DOPE gives the best efficiency of transfection for tumor cells in vivo. We also showed that a strong anti-H-2Kb allo-reactive cytotoxic T lymphocyte (CTL) response could be generated following in vivo immunization of AKR/J mouse spleens with the H-2Kb gene and **DC-cho1** cationic liposomes. The direct immunization of mouse spleens to induce cell-mediated immunity against exogenous antigens may allow alternative treatment strategies for cancer immunotherapy.

L8 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:290545 CAPLUS
 DN 126:263153
 TI Parainfluenza virus glycoproteins and **vaccines**
 IN Cates, George A.; Ewasyshyn, Mary E.; Fahim, Raafat E. F.; Jackson, Gail E. D.; Klein, Michel H.; Symington, Alison L.
 PA Connaught Laboratories Limited, Can.; Cates, George A.; Ewasyshyn, Mary E.; Fahim, Raafat E. F.; Jackson, Gail E. D.; Klein, Michel H.; Symington, Alison L.
 SO PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9711093	A2	19970327	WO 1996-CA639	19960923
	WO 9711093	A3	19970515		
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA			
	CA 2232515	AA	19970327	CA 1996-2232515	19960923
	AU 9669820	A1	19970409	AU 1996-69820	19960923
	AU 712213	B2	19991104		
	EP 851873	A2	19980708	EP 1996-930931	19960923
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	CN 1202905	A	19981223	CN 1996-198453	19960923
	JP 11513372	T2	19991116	JP 1996-512271	19960923
	BR 9610590	A	20001024	BR 1996-10590	19960923
	US 6165774	A	20001226	US 1998-43477	19980808
	AU 9932228	A1	19990805	AU 1999-32228	19990526
	AU 727996	B2	20010104		
	AU 9932229	A1	19990819	AU 1999-32229	19990526
	AU 732951	B2	20010503		
	AU 9932230	A1	19990819	AU 1999-32230	19990526
	AU 718025	B2	20000406		
PRAI	US 1995-532464	A	19950922		
	AU 1996-69820	A3	19960923		
	WO 1996-CA639	W	19960923		
AB	The hemagglutinin-neuraminidase (HN) and fusion (F) glycoproteins are coisolated and copurified from the parainfluenza virus type 1 (PIV-1) and parainfluenza virus type 3 (PIV-3). The HN and F glycoprotein are sep. isolated and purified from parainfluenza virus type 2 (PIV-2). The purifn. is done by ion exchange chromatog., gel filtration, and tangential flow ultrafiltration. The glycoproteins formulated as vaccines , are highly immunogenic and protect relevant animal models against parainfluenza challenge. A vaccine contg. the HN and F glycoproteins from PIV-3 was safe and immunogenic in adults and children. A trivalent vaccine contg. HN and F glycoproteins from PIV-1, PIV-2 and PIV-3 generated an immune response capable of neutralizing each of the viruses.				

L8 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:260263 CAPLUS
 DN 122:29689
 TI Induction of alloreactive cytotoxic T lymphocytes by intra-splenic

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 2000:34710 CAPLUS

DN 132:83616

TI Use of an **amphipathic** compound for providing an **adjuvant** to a subunit vaccine

IN Darbouret, Anne; Brunel, Florence; Ronco, Jorge

PA Pasteur Merieux Serums & Vaccins, Fr.

SO PCT Int. Appl., 11 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000001345	A2	20000113	WO 1999-FR1604	19990702
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2781160	A1	20000121	FR 1998-8700	19980703
	FR 2781160	B1	20000818		
	CA 2337048	AA	20000113	CA 1999-2337048	19990702
	AU 9946217	A1	20000124	AU 1999-46217	19990702
	EP 1093382	A2	20010425	EP 1999-929389	19990702
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6472159	B1	20021029	US 2001-720863	20010416
PRAI	FR 1998-8700	A	19980703		
	WO 1999-FR1604	W	19990702		
AB	An amphipathic compd. for prepg. a vaccine compn. comprising at least a subunit antigen to be administered to target populations comprising non-responders to said antigen is disclosed. A particular amphipathic compd. is 3- β -[N-(N',N'-dimethylaminoethane)- carbamoyl] cholesterol (I). A vaccine contained hepatitis B antigen 1 μ g, I 0.5 mg, and buffer q.s. 0.5 mL. The efficacy of the vaccine in immunization of guinea pigs is shown.				

L9 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 1996:437984 CAPLUS

DN 125:96041

TI Adjuvant for vaccines comprising a sterol-derived lipophilic group bound to a cationic group

IN Haensler, Jean; Trannoy, Emmanuelle; Ronco, Jorge

PA Pasteur Merieux Serums et Vaccins, Fr.

SO PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9614831	A1	19960523	WO 1995-FR1495	19951114
	W:				
	AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
	RW:				
	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,				

IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,
NE, SN, TD, TG

FR 2726764	A1	19960515	FR 1994-13606	19941114
FR 2726764	B1	19970131		
CA 2205022	AA	19960523	CA 1995-2205022	19951114
AU 9641802	A1	19960606	AU 1996-41802	19951114
AU 706131	B2	19990610		
EP 793484	A1	19970910	EP 1995-940309	19951114
EP 793484	B1	20030219		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE

CN 1168629	A	19971224	CN 1995-196601	19951114
CN 1096851	B	20021225		
JP 11500409	T2	19990112	JP 1995-515800	19951114

PRAI FR 1994-13606 A 19941114
WO 1995-FR1495 W 19951114

AB An **amphipathic** compd. including a sterol-derived lipophilic grouping bound to a cationic grouping for use as an **adjuvant** in the delivery of a vaccine compn. In a particular embodiment, the lipophilic grouping is a **cholesterol** deriv. and the cations grouping is a quaternary ammonium or a protonable amine. A vaccine compn. including one or more antigens with at least one amphipathic compd. having a sterol-derived lipophilic grouping bound to a cationic grouping, is also disclosed. A soln. of 2.25 g cholesteryl chloroformate in 5 mL chloroform was stirred with a soln. of 2 mL N,N-dimethylethylenediamine in 3 mL chloroform at 0.degree. followed by evapn. of the solvent and the purifn. of 3.beta.-[N-(N'N'-dimethylaminoethane)-**carbamoyl**]-**cholesterol** (I) by recrystn. Thus, 300 mg I was dissolved in 100 .mu.L ethanol and 75 .mu.L of this soln was injected to 3 mL of water at 45.degree. and stirred for 5 min. The micellar suspension thus obtained was mixed with 200 .mu.L of a monovalent influenza vaccine and divided in 0.3 mL doses. The immunol. response of guinea pigs to the above vaccine was studied.

L9 ANSWER 3 OF 4 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V.
AN 1984:14139828 BIOTECHNO

TI Further study of biological activities of chemically synthesized analogues of lipid A in artificial membrane vesicles

AU Yaduda T.; Kanegasaki S.; Tsumita T.; et al.

CS The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108, Japan.

SO European Journal of Biochemistry, (1984), 140/2 (245-248)

CODEN: EJBCEI

DT Journal; Article

CY Germany, Federal Republic of

LA English

AB In the previous paper .cents.Eur. J. Biochem. 124, 405 (1982)!, we demonstrated that chemically synthesized lipid A analogues such as the 1-monophosphate or 1,4'-diphosphate or 6-O-(2-deoxy-2-tetradecanoylamino-6-O-tetradecanoyl-D-glucopyranosyl)-2-deoxy-2-tetradecanoylamino-3,4-di-O-tetradecanoyl-D-glucopyranose enhanced immunogenicity of liposomal model membranes sensitized with **amphipathic** antigen when they were incorporated in the same liposomes. Here we extend the observation by testing the recently synthesized analogues including diglucosamine analogues carrying hydroxy and acyloxy fatty acids. Among the analogues tested, those which showed higher **adjuvant** and mitogenic activities in the liposomal system were N-acylated and O-acylated .beta.-1,6-linked D-glucosamine disaccharides carrying either amide-bound 3-hydroxytetradecanoic acids in addition to phosphate in position 1 of the reducing sugar or amide-bound 3-tetradecanoyloxytetradecanoic acids. The analogue carrying both amide-bound 3-hydroxytetradecanoic acids and phosphate in position 4 of the non-reducing sugar showed weak

adjuvant activity and marginal mitogenic activity.

L9 ANSWER 4 OF 4 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AN 84114776 EMBASE

DN 1984114776

TI Further study of biological activities of chemically synthesized analogues of lipid A in artificial membrane vesicles.

AU Yaduda T.; Kanegasaki S.; Tsumita T.; et al.

CS The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108, Japan

SO European Journal of Biochemistry, (1984) 140/2 (245-248).

CODEN: EJBCAI

CY Germany

DT Journal

FS 037 Drug Literature Index

029 Clinical Biochemistry

026 Immunology, Serology and Transplantation

LA English

AB In the previous paper [Eur. J. Biochem. 124, 405 (1982)], we demonstrated that chemically synthesized lipid A analogues such as the 1-monophosphate or 1,4'-diphosphate or 6-O-(2-deoxy-2-tetradecanoylamino-6-O-tetradecanoyl-D-glucopyranosyl)-2-deoxy-2-tetradecanoylamino-3,4-di-O-tetradecanoyl-D-glucopyranose enhanced immunogenicity of liposomal model membranes sensitized with **amphipathic** antigen when they were incorporated in the same liposomes. Here we extend the observation by testing the recently synthesized analogues including diglucosamine analogues carrying hydroxy and acyloxy fatty acids. Among the analogues tested, those which showed higher **adjuvant** and mitogenic activities in the liposomal system were N-acylated and O-acylated .beta.-1,6-linked D-glucosamine disaccharides carrying either amide-bound 3-hydroxytetradecanoic acids in addition to phosphate in position 1 of the reducing sugar or amide-bound 3-tetradecanoyloxytetradecanoic acids. The analogue carrying both amide-bound 3-hydroxytetradecanoic acids and phosphate in position 4 of the non-reducing sugar showed weak **adjuvant** activity and marginal mitogenic activity.